Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Research & Development (2016 - 2025)

Historic Research & Development for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to $469000.0.

  • Alaunos Therapeutics' Research & Development rose 22797.2% to $469000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $915000.0, marking a year-over-year decrease of 3379.16%. This contributed to the annual value of $362000.0 for FY2024, which is 9777.63% down from last year.
  • Latest data reveals that Alaunos Therapeutics reported Research & Development of $469000.0 as of Q3 2025, which was up 22797.2% from $185000.0 recorded in Q2 2025.
  • In the past 5 years, Alaunos Therapeutics' Research & Development ranged from a high of $14.5 million in Q3 2021 and a low of -$86000.0 during Q4 2024
  • Its 5-year average for Research & Development is $4.4 million, with a median of $4.4 million in 2023.
  • Its Research & Development has fluctuated over the past 5 years, first tumbled by 10921.76% in 2024, then surged by 22797.2% in 2025.
  • Over the past 5 years, Alaunos Therapeutics' Research & Development (Quarter) stood at $8.2 million in 2021, then plummeted by 31.76% to $5.6 million in 2022, then tumbled by 83.36% to $933000.0 in 2023, then crashed by 109.22% to -$86000.0 in 2024, then skyrocketed by 645.35% to $469000.0 in 2025.
  • Its Research & Development stands at $469000.0 for Q3 2025, versus $185000.0 for Q2 2025 and $347000.0 for Q1 2025.